 |
市場調査レポート
商品コード
1189196
ハンチントン病の世界市場：市場規模 - 治療法別、地域別展望、競合戦略、セグメント別予測（～2032年）Huntington's Disease Market Size-By Treatment - Regional Outlook, Competitive Strategies and Segment Forecast to 2032 |
||||||
| ハンチントン病の世界市場：市場規模 - 治療法別、地域別展望、競合戦略、セグメント別予測（～2032年） |
|
出版日: 2022年12月29日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 225 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 目次
世界のハンチントン病の市場規模は、2032年までに26億5,000万米ドルに達し、CAGRで19.83%の成長が予測されています。
新製品創出のための多額の研究開発費、研究提携、欧米諸国におけるハンチントン病の高い有病率などの結果、世界市場は拡大しつつあります。
当レポートでは、世界のハンチントン病市場について調査し、市場力学、競合情勢、治療法・地域別の市場分析、企業プロファイル等に関する情報を提供しています。
目次
第1章 イントロダクション
第2章 調査手法
- 調査データソース
- 市場規模の推定
- データの三角測量
第3章 エグゼクティブサマリー
第4章 市場力学
- 促進要因、抑制要因、機会、課題の分析
- 促進要因
- 抑制要因
- 機会
- 課題
- 世界のハンチントン病市場におけるCOVID-19の影響
第5章 市場変数と展望
- SWOT分析
- 強み
- 弱み
- 機会
- 脅威
- PESTEL分析
- 政治情勢
- 経済情勢
- 社会情勢
- 技術情勢
- 環境情勢
- 法的情勢
- ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入者の脅威
- 競合企業間の敵対関係
- ヒートマップ分析
第6章 競合情勢
- 世界のハンチントン病の製造拠点分布、販売エリア、製品タイプ
- 世界のハンチントン病市場における合併・買収、パートナーシップ、製品の発売、コラボレーション
第7章 世界のハンチントン病市場：治療法別（2019年～2032年（100万米ドル））
- 対症療法
- 疾患修飾療法
第8章 世界のハンチントン病市場：地域別（2019年～2032年（100万米ドル））
- 世界のハンチントン病の市場規模・市場シェア：地域別（2019年～2025年）
- 世界のハンチントン病の市場規模・市場シェア：地域別（2026年～2032年）
- アジア太平洋
- オーストラリア
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- 欧州
- フランス
- ドイツ
- イタリア
- スペイン
- 英国
- その他の欧州
- 中東・アフリカ
- サウジアラビア王国
- アラブ首長国連邦
- その他の中東・アフリカ
- 北米
- カナダ
- メキシコ
- 米国
- ラテンアメリカ
- アルゼンチン
- ブラジル
- その他のラテンアメリカ
第9章 企業プロファイル
- Annexon Biosciences
- 企業概要
- 財務見通し
- 製品概要
- 最近の開発
- Bausch Health Companies Inc.
- Dr. Reddy's Laboratories Ltd
- Eli Lilly And Company
- H. Lundbeck A/S
- Hetero
- Hikma Pharmaceuticals PLC
- Lupin
- Medesis pharma SA
- Mitochon Pharmaceuticals
- Neurocrine bioscience Inc.
- Novartis
- PTC Therapeutics, Inc.
- SOM Biotech
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- UniQure
- Vaccinex, Inc.
第10章 略語一覧
第11章 参照リンク
第12章 結論
第13章 調査範囲
Global Huntington's Disease Market Overview:
According to SPER Market Research, the Global Huntington's Disease Market is estimated to reach USD 2.65 billion by 2032 with a CAGR of 19.83%.
The global market for Huntington's disease is expanding as a result of significant R&D expenditures for the creation of novel products, research partnerships, and the high prevalence of HD in western nations. An uncommon hereditary neurological disorder that affects multiple generations, is Huntington's disease. People in adult age are affected, which limits their ability to work, take care of their families, and finally finish everyday duties. The numbers vary between regions, which can be attributed to differences in case ascertainment and diagnostic standards. Also, the incidence varies between regions, which can be attributed to differences in case ascertainment and diagnostic standards. As a result, larger repeats may be more common than anticipated in the general population. While Europe, North America, and Australia have greater prevalence's, the Asian population has continuously had a lower prevalence. The key players are concentrating on the research and development of HD symptomatic treatments. An investigational medication called SRX246 is being created by Azevan Pharmaceuticals to treat the neuropsychiatric signs and symptoms of Huntington's disease. The medicine SRX246 functions by obstructing the brain's vasopressin 1a (V1a) receptor. The primary vasopressin receptor in the nervous system is the V1a receptor. By blocking the V1a receptor and preventing vasopressin from binding to the receptor, SRX246 causes the agitated and violent behaviour that is typical of people with Huntington's disease. The medications that are now approved, however, only treat the symptoms of the condition and offer palliative care. While drugs might lessen a patient's symptom intensity, they are frequently linked to side effects such as somnolence, gait problems, dysphagia, and apathy that can seriously impair a patient's quality of life. It is crucial to assess how these patients' Health-related Quality of Life (HRQOL) is affected given the lack of treatment for the illness. Early to mid-stage HD patients require integrated multidisciplinary healthcare treatments, such as counselling and assessments of cognitive function. As a result of various medicines' inability to show effectiveness or their high levels of toxicity, drug development for HD has encountered considerable challenges. Patients with early manifest and prodromal HD did not meet the pre-specified co-primary outcomes in Vaccinex Inc.'s phase II study of pepinemab. The Huntington's disease Cognitive Assessment Battery family comprising two cognitive tests and the Clinical Global Impression of Change (CGIC) did not reach statistical significance in the SIGNAL study's early manifestation sample. Due to the availability of medicine and patent protection, the symptomatic treatment category had the highest revenue share in the last year. The entrance of SAGE-718 and Cellavita-HD is expected to make disease-modifying treatments the market sector with the fastest growth over the next years. Instead of targeting the mutant protein, businesses are now concentrating on the development of drugs that can be injected into the brain to prevent the creation of mutant HTT protein. Early-stage pharmaceuticals with innovative targets include Cellavita HD (stem cell treatment) by Cellavita and Azidus Brazil, mHTT ZFP by Sangamo Therapeutics, Inc., and AMT-130 by UniQure (gene therapy). The market for the treatment of Huntington's disease is now dominated by the symptomatic treatment sector, which also had the highest revenue share. The availability of symptom management treatments and the patent protection afforded to these medications are to blame for this rise. When it comes to first-line treatment for chorea brought on by Huntington's disease, Xenazine and Austedo are recommended.
Impact of COVID-19 on the Global Huntington's Disease Market:
The worldwide COVID-19, however, caused a slowdown in the therapy market for Huntington's disease. Antidepressants, antipsychotics, and anticonvulsants were among the off-label medications sold by online pharmacies during the epidemic to treat HD symptoms. Clinical experiments during the COVID-19 pandemic were halted because to the government shutdown.
Scope of the report:
- Market size available for the years: 2019-2032
- Base year considered: 2021
- Forecast Period: 2022-2032
- Segments Covered: By Treatment
- Regions Covered: Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
- Companies Covered: Annexon Biosciences, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, H. Lundbeck A/S, Hetero, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc., SOM Biotech, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UniQure, Vaccinex, Inc.
Global Huntington's Disease Market Segmentation:
- By Treatment: Based on the Treatment, Global Huntington's Disease Market is segmented as; Symptomatic treatment, Disease-modifying therapies.
- By Region: Due to improved reimbursement infrastructure and the significant financial burden of HD in the United States and Canada, North America, which accounted for the greatest revenue share in previous year, is anticipated to dominate the market throughout the forecast period.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Global Huntington's Disease Market
5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4. Heat map analysis
6. Competitive Landscape
- 6.1 Global Huntington's Disease Manufacturing Base Distribution, Sales Area, Product Type
- 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Huntington's Disease Market
7. Global Huntington's Disease Market, By Treatment, 2019-2032 (USD Million)
- 7.1 Symptomatic treatment
- 7.2 Disease-modifying therapies
8. Global Huntington's Disease Market, By Region, 2019-2032 (USD Million)
- 8.1 Global Huntington's Disease Size and Market Share by Region (2019-2025)
- 8.2 Global Huntington's Disease Size and Market Share by Region (2026-2032)
- 8.3 Asia-Pacific
- 8.3.1 Australia
- 8.3.2 China
- 8.3.3 India
- 8.3.4 Japan
- 8.3.5 South Korea
- 8.3.6 Rest of Asia-Pacific
- 8.4 Europe
- 8.4.1 France
- 8.4.2 Germany
- 8.4.3 Italy
- 8.4.4 Spain
- 8.4.5 United Kingdom
- 8.4.6 Rest of Europe
- 8.5 Middle East and Africa
- 8.5.1 Kingdom of Saudi Arabia
- 8.5.2 United Arab Emirates
- 8.5.3 Rest of Middle East & Africa
- 8.6 North America
- 8.6.1 Canada
- 8.6.2 Mexico
- 8.6.3 United States
- 8.7 Latin America
- 8.7.1 Argentina
- 8.7.2 Brazil
- 8.7.3 Rest of Latin America
9. Company Profiles
- 9.1 Annexon Biosciences
- 9.1.1 Company details
- 9.1.2 Financial outlook
- 9.1.3 Product summary
- 9.1.4 Recent developments
- 9.2 Bausch Health Companies Inc.
- 9.2.1 Company details
- 9.2.2 Financial outlook
- 9.2.3 Product summary
- 9.2.4 Recent developments
- 9.3 Dr. Reddy's Laboratories Ltd
- 9.3.1 Company details
- 9.3.2 Financial outlook
- 9.3.3 Product summary
- 9.3.4 Recent developments
- 9.4 Eli Lilly And Company
- 9.4.1 Company details
- 9.4.2 Financial outlook
- 9.4.3 Product summary
- 9.4.4 Recent developments
- 9.5 H. Lundbeck A/S
- 9.5.1 Company details
- 9.5.2 Financial outlook
- 9.5.3 Product summary
- 9.5.4 Recent developments
- 9.6 Hetero
- 9.6.1 Company details
- 9.6.2 Financial outlook
- 9.6.3 Product summary
- 9.6.4 Recent developments
- 9.7 Hikma Pharmaceuticals PLC
- 9.7.1 Company details
- 9.7.2 Financial outlook
- 9.7.3 Product summary
- 9.7.4 Recent developments
- 9.8 Lupin
- 9.8.1 Company details
- 9.8.2 Financial outlook
- 9.8.3 Product summary
- 9.8.4 Recent developments
- 9.9 Medesis pharma SA
- 9.9.1 Company details
- 9.9.2 Financial outlook
- 9.9.3 Product summary
- 9.9.4 Recent developments
- 9.10 Mitochon Pharmaceuticals
- 9.10.1 Company details
- 9.10.2 Financial outlook
- 9.10.3 Product summary
- 9.10.4 Recent developments
- 9.11 Neurocrine bioscience Inc.
- 9.11.1 Company details
- 9.11.2 Financial outlook
- 9.11.3 Product summary
- 9.11.4 Recent developments
- 9.12 Novartis
- 9.12.1 Company details
- 9.12.2 Financial outlook
- 9.12.3 Product summary
- 9.12.4 Recent developments
- 9.13 PTC Therapeutics, Inc.
- 9.13.1 Company details
- 9.13.2 Financial outlook
- 9.13.3 Product summary
- 9.13.4 Recent developments
- 9.14 SOM Biotech
- 9.14.1 Company details
- 9.14.2 Financial outlook
- 9.14.3 Product summary
- 9.14.4 Recent developments
- 9.15 Sun Pharmaceutical Industries Ltd.
- 9.15.1 Company details
- 9.15.2 Financial outlook
- 9.15.3 Product summary
- 9.15.4 Recent developments
- 9.16 Teva Pharmaceutical Industries Ltd.
- 9.16.1 Company details
- 9.16.2 Financial outlook
- 9.16.3 Product summary
- 9.16.4 Recent developments
- 9.17 UniQure
- 9.17.1 Company details
- 9.17.2 Financial outlook
- 9.17.3 Product summary
- 9.17.4 Recent developments
- 9.18 Vaccinex, Inc.
- 9.18.1 Company details
- 9.18.2 Financial outlook
- 9.18.3 Product summary
- 9.18.4 Recent developments
